We and others have shown that the Bcr-Abl oncoprotein binds activators of the Ras pathway such as Grb2 and Shc. Grb2 binding is mediated through a phosphorylated tyrosine residue (Y177) located within a consensus Grb2 binding site encoded by the ®rst exon of the BCR gene. Our results indicate that P160 BCR is tyrosine phosphorylated at the same site by Bcr-Abl in kinase assays (Puil et al., 1994) . We performed experiments to determine whether Bcr, which was tyrosine phosphorylated within cells by activated c-Abl, could also bind Grb2, and whether phosphotyrosine 177 was the major binding site. Complexes between Bcr and Abl were detected in a hemopoietic cell line lacking Bcr-Abl and in COS1 cells coexpressing both Bcr and Abl proteins. P160 BCR was tyrosine phosphorylated in COS1 cells coexpressing Abl and Bcr proteins. Similarly, various deletion mutants of Bcr including BCRN553, BCRN413 and BCRN221 were tyrosine phosphorylated by activated c-Abl whereas BCRN159 was not. Wild-type Bcr and Bcr Y177F were examined under these conditions for their ability to co-precipitate with Grb2. The results showed that while wild-type tyrosine phosphorylated Bcr eciently bound Grb2, tyrosine phosphorylated Bcr Y177F had greatly reduced Grb2-binding ability. Studies with GST-SH2 (Grb2) revealed that tyrosine phosphorylated Bcr was able to bind to GST SH2 (Grb2) but tyrosine phosphorylated Bcr Y177F was de®cient in binding. These results indicate that the Bcr protein when phosphorylated at tyrosine 177 binds Grb2, thereby implicating Bcr as a potantial activator of the Ras pathway.
The BCR gene was ®rst discovered because of its association with Philadelphia chromosome (Ph)-positive leukemias (Nowell et al., 1960; Priest et al., 1980; Champlin and Golde, 1985) . The BCR gene encodes a 160 kDa protein that contains a novel serine/threonine kinase (Stam et al., 1987; Li et al., 1989; Maru and Witte, 1991) and a Rac Gap function (Diekmann et al., 1991) . In addition, the central region of Bcr has homology to the DBL gene, known to be associated with a guanine-nucleotide exchange activity (Ron et al., 1991) . Recent studies indicate that the DBL homology domain within Bcr is functional (Chuang et al., 1995) . Patients acquiring the Ph fuse 5' sequences of BCR to the bulk of the ABL gene (Shtivelman et al., 1986; Hermans et al., 1987) . The resulting Bcr-Abl oncoprotein contains either 426 amino acids of Bcr or 902/926 amino acids of Bcr fused to the Abl protein lacking the ®rst exon coding sequences (Shtivelman et al., 1987) . The resulting BcrAbl proteins are termed P185 BCR-ABL or P210 BCR-ABL. Unlike the normal Abl protein, both BcrAbl proteins possess an activated tyrosine protein kinase activity (Konopka et al., 1984; Kloetzer et al., 1985; Kurzrock et al., 1987) .
The BCR-ABL gene is a major factor in causing and maintaining Ph-positive leukemia. Mice transplanted with marrow cells expressing the Bcr-Abl oncoprotein develop a number of leukemias, some of which resemble chronic myelogenous leukemia (CML) (Daley et al., 1990) . Transgenic mice expressing the P185 BCR-ABL protein develop acute lymphocytic leukemia (Heisterkamp et al., 1990) .
Bcr-Abl proteins form complexes with several proteins including p120 Ras Gap (Druker et al., 1992) , P160 BCR (Campbell et al., 1990 ), 14-3-3 (Reuther et al., 1994) , Crkl (ten Hoeve et al., 1994) , Grb2 (Pendergast et al., 1993) , Shc and Grb2 (Pull et al., 1994; Tauchi et al., 1994) and an identi®ed protein termed ph-P53 (Li et al., 1988) . More recently, BCRAbl was reported to induce multimeric complexes of signaling proteins that include p120 CBL, Pl-3 kinase, c-Crk or Crkl, c-Abl and Bcr-Abl (Sattler et al., 1996) . Crkl and Grb2 are members of the SH2/SH3 containing proteins, which are part of an ever expanding group of proteins involved in signal transduction. Because of past results in a number of systems, it is clear that Grb2 is an activator of the Ras pathway. Grb2 binds to the consensus sequence YVNV when the tyrosine residue is phosphorylated (Zhou et al., 1993) . This sequence is found in the ®rst exon coding region of BCR. We ®rst demonstrated that Bcr sequences contain several tyrosine residues that are major targets for autophosphorylation by Bcr-Abl . These same sites are also phosphorylated in trans on P160 BCR found in complexes with Bcr-Abl oncoproteins .
We showed that Bcr ®rst exon peptide sequences containing phosphotyrosine 177 labeled in the kinase reaction in vitro speci®cally bound to the SH2 domain of Grb2 (Puil et al., 1994) . Both Bcr-Abl and Bcr contained this phosphotyrosine peptide sequence, indicating that Bcr if phosphorylated on tyrosine 177 will also bind to Grb2. In the experiments shown below we showed that Bcr and Abl formed stable complexes in cell lines and that full length Bcr and amino terminal fragments of Bcr containing tyrosine 177 were tyrosine phosphorylated by activated Abl.
We demonstrated that tyrosine phosphorylated Bcr coprecipitated with Grb2 whereas mutant Bcr (Y177F) was defective in binding Grb2.
Previous results demonstrated that c-Abl and Bcr when overexpressed in Baculovirus infected cells form complexes (Pendergast et al., 1991a) . We performed experiments to determine whether Bcr and Abl form complexes in a human pre-B cell line, SMS-SB (Smith et al., 1981) . In these experiments, we screened either anti-Bcr immunoprecipitates for the presence of P145 ABL or anti-Abl immunoprecipitates for P160 BCR under conditions that allow detection of proteinprotein complexes (Cambell et al., 1990; Liu et al., 1993) . Immunoprecipitates were denatured, fractionated by SDS-polyacrylamide gel electrophoresis, and blotted onto Immobilon P ®lters (Millipore, Bedford, MA) for Western blotting. Anti-Bcr (a peptide generated monoclonal antibody termed P5C, Li et al., 1989) (Figure 1b, lane 2) . These results establish that a human hematopoietic cell line expressing both Bcr and Abl contain stable complexes of Bcr and Abl and that these complexes can also be detected in COS1 cells coexpressing both proteins.
Our previous results have established that P160 BCR is tyrosine phosphorylated by Bcr-Abl . It was of interest to determine whether Bcr can be tyrosine phosphorylated by activated c-Abl. Therefore, we examined COS1 cells overexpressing normal Abl in the presence and absence of Bcr. In these experiments COS1 cells were transiently transfected with BCR-ABL or ABL genes in the presence and absence of either full length BCR or deletion mutants of BCR lacking varying lengths of the 3' end of the ®rst exon ( Figure  3 ). The methods used were as described by Lu et al. (1993) . Brie¯y, BCR-ABL and ABL genes were inserted into the pSG5 vector (Stratagene, La Jolla, CA), which contains the early SV40 promoter to enhance in vivo expression in cells expressing the large T antigen. COS1 cells were transfected, and extracts were analysed by Western blotting with either anti-Abl (8E9) monoclonal antibody (Guo et al., 1994) , anti-Bcr monoclonal antibody (7C6, Santa Cruz Biotechnology, Santa Cruz, CA) or rabbit anti-peptide antibodies made against Bcr 1 ± 16 (the N-terminus) or BCR(1256 ± 1271) (the C-terminus) (Campbell et al., 1990) . Immunoprecipitates were denatured and fractionated by SDS gel electrophoresis, and blotted onto Immobilon ®lters for Western blotting. Simultaneous overexpression of both P145 ABL (1b) and full length Bcr (P160 BCR) induced tyrosine phosphorylation of P160 BCR (Figure 2 , lane 3), which was lacking in the anti-phosphotyrosine (Transduction Labs, Lexington, KY) blot of COS1 cells expressing Bcr alone (lanes 1 and 6) or Abl alone (lanes 2 and 4). That this tyrosine phosphorylated protein is P160 BCR, is indicated by its presence only in COS1 cells coexpressing human P160 BCR and activated c-Abl (lanes 3, 5 and 7). The identity of the 175 kd protein phosphorylated on tyrosine residues (lane 3) present in cells coexpressing both BCR and ABL is unknown. Possibly, it is a hyperphosphorylated form of P160 BCR or another form of BCR, which is present in trace amounts (compare lanes 3 and 7).
In order to investigate the in vivo tyrosine phosphorylation sites of Bcr, we expressed deletion mutants of BCR (Figure 3 ) either alone or in the presence of BCR-ABL (Figure 4a ). Several deletion mutants of BCR were constructed that would encode the varying lengths of BCR N-terminal amino acids. BCRN553 (encoding the N-terminal 553 residues of Bcr), BCRN413, BCRN221 and BCRN159 were made by inserting a Xba1 linker containing stop codon in all three frames into Sac1, BglII, XhoI or BamHI sites within the ®rst exon of BCR. BCRN413 contained all 11 tyrosine residues encoded by the ®rst exon of BCR (BCR ®rst exon encoding 426 amino acids) (Figure 3) . Our ®ndings have shown that tyrosines 177 (Puil et al., . Blots were treated with anti-Bcr(7C6) to detect Bcr and with anti-Abl 8E9 to detect Abl, using standard ECL procedures (Guo et al., 1994) 1994), 283 and 360 (Liu et al., 1996) are phosphorylated within Bcr-Abl and Bcr. BCRN221 contained tyrosines 58, 70 and 177; BCRN159 contained tyrosines 58 and 70 of Bcr (Figure 3 ). Western blotting using anti-BCR N-terminal (1 ± 16) antibody established that BCRN413, BCRN221, and BCRN159 mutants can either be expressed alone ( Figure 4 , lanes 2 ± 4) or coexpressed with P210 BCR-ABL (Figure 4a , lanes 5 ± 7) in COS1 cells. These mutant proteins were expressed in COS1 cells with apparent molecular weights of about 60 kDa, 30 kDa or 20 kDa, respectively, (Figure 4a , lanes 2 ± 7, marked with open circles). As expected, overexpressing BCRN413, BCRN221 and BCRN159 alone did not result in tyrosine phosphorylation of these protein fragments as measured by anti-phosphotyrosine antibody Western blotting (Figure 4a, lanes 9 ± 11) .
However except for BCRN159, coexpressing BCRN221 or BCRN413 with P210 BCR-ABL induced their phosphorylation (lanes 12 ± 14) .
The normal cellular Abl protein is a highly regulated tyrosine kinase that contains the typical Src homology domains in addition to a unique C-terminal domain. The endogenous c-Abl protein isolated from cells has been shown to lack tyrosine kinase activity, possibly as a result of some protein inhibitor(s) (Pendergast et al., 1991b) . Thus, overexpression of c-ABL(1b) in COS1 cells results in activation of its tyrosine kinase activity as measured by both in vitro immunokinase assays (not shown) and anti-phosphotyrosine Western blotting of the cell lysates (Figure 4b, lanes 6 ± 8) . These results are consistent with the previous ®nding by others (Pendergast et al., 1991b) . Coexpression of the Bcr mutants with P145 Abl(1b) resulted in tyrosine phosphorylation of BCRN221 and BCRN413 and autophosphorylation of P145 ABL as well (Figure 4b , lanes 7 and 8). Similarly, BCRN553 was also an excellent substrate for c-Abl (not shown). BCRN159 lacked detectable phosphotyrosine under these conditions (lane 6). These results indicate that protein sequences encoded by the ®rst exon of BCR contain major sites for phosphorylation by the activated Abl kinases. The fact that coexpression of either BCRN221 or BCRN159 with P145 ABL or P210 BCR-ABL resulted in tyrosine phosphorylation of BCRN221 but not BCRN159 indicates that tyrosine 177 of Bcr is phosphorylated in vivo by these activated tyrosine kinases. The lack of phosphorylation of BCRN159 suggests that tyrosines 58 and 70 are not phosphorylated by c-Abl and Bcr-Abl. However, we cannot eliminate the possibility that tyrosines 58 and 70 could be phosphorylated within the intact Bcr protein.
It is well known that phosphotyrosine 177 within Bcr sequences of BCR-ABL is required for its direct interaction with SH2 domain of Grb2, an SH2 and SH3 domain-containing adaptor molecule (Pendergast et al., 1993; Puil et al., 1994) . In ®broblasts, this interaction is essential for activation of Ras functions and transformation by BCR-ABL (Pendergast et al., 1993) . Since we have shown that activated P145 ABL can transphosphorylate Bcr and amino terminal Bcr protein fragments containing tyrosine 177 (Figure 4) , it was of interest to determine whether tyrosine phosphorylated P160 BCR can also bind to the Grb2 protein within cells and whether the Y177F mutant of P160 BCR retains the ability to bind Grb2. Commercial anti-Grb2 was obtained from Transduction Laboratories (Lexington, KY). BCR (Y177F) was prepared as described (Liu et al., 1996) . COS1 cells expressed an endogenous simian Grb2 protein that can be easily detected by Western blotting (not shown). Wild-type P160 BCR or the Y177F mutant were separately expressed or coexpressed with P145 ABL (1b) in COS1 cells. Two days after transfection, cells were harvested and cell lysates clari®ed by ultracentrifugation were incubated with anti-Bcr C-terminal (1256 ± 1271) antibody and Bcr proteins were detected by Western blotting using a second antibody to Bcr (7C6, Santa Cruz Biotechnology, Santa Cruz, CA) (Figure 5a ). Both wild-type Bcr and Bcr Y177F were stably produced in COS1 cells (Figure 5a, lanes 2 and  3) . Coexpression of P145 ABL along with Bcr reduced the level of Bcr expression by about 50% (Figure 5a , 2 and 3) . Human P145 ABL expression was only detected in human c-ABL transfected COS1 cells (Figure 5d , lanes 4 ± 6); only low levels of simian P145 ABL were detected in COS1 cells (Figure 5d , lanes 1 ± 3). Bands were detected using ECL methods (Guo et al., 1994) To assess the degree of Grb2 binding to Bcr, antiBcr(1256 ± 1271) immunoprecipitates from the same extracts were probed with anti-Grb2 antibody ( Figure  5b) . The results showed no signi®cant Grb2 binding to Bcr in untransfected COS1 cells (Figure 5b , lane 1) and only trace levels of Grb2 binding to Bcr in BCR transfected cells, either wild-type or mutant Bcr ( Figure  5b, lanes 2 and 3) . Co-expression of high levels of human P145 ABL greatly increased the level of Grb2 binding to wild-type Bcr (Figure 5b, lane 5) , but Grb2 binding to Bcr Y177F was greatly reduced (Figure 5b , lane 4), thereby directly implicating Bcr tyrosine 177 in this binding. Quantitation of the appropriate proteins using a volume densitometer indicated that Bcr Y177F bound 75% less Grb2 than wild-type Bcr. These results indicate that Bcr when phosphorylated on tyrosine 177 eciently binds Grb2.
These extracts were also incubated with GST-SH2 (Grb2) to assess the ability of Bcr to bind the SH2 domain of Grb2 (Figure 5c ). The GST-SH2 (Grb2) was obtained from the laboratory of Tony Pawson (Mount Sinai Hospital Research Institute at Toronto, Ontario, Canada) (Puil et al., 1994) . The SH2 domain of Grb2 bound signi®cant levels of tyrosine phosphorylated P160 BCR (Figure 5c , lane 5), but no binding was detected by non-tyrosine phosphorylated Bcr (Figure 5c, lane 3) . Tyrosine phosphorylated Bcr Y177F showed little binding of GST-SH2 (Grb2) (Lane 4). GST alone also exhibited no binding to tyrosine phosphorylated Bcr (not shown).
To con®rm the presence of a Grb2/Bcr complexes in cells coexpressing Bcr and Abl, we analysed anti-Grb2 immunoprecipitates by immunoblotting with antiBcr(1 ± 16). The results indicated that Grb2 and Bcr coprecipitated only when wild-type Bcr was coexpressed with c-Abl (Figure 6a, lane 2) . The amount of such complexes was greatly reduced in cells coexpressing Bcr Y177F and c-Abl (lane 3). These same Grb2 immunoprecipitates were found to contain similar levels of Grb2 (Figure 6b) .
These results indicate that, like Bcr-Abl, the phosphotyrosine 177 containing sequence of P160 BCR is able to bind to Grb2 within live cells. These ®ndings indicate that the c-Abl protein, when activated, has the potential to activate Ras pathway in normal hematopoietic cells by phosphorylation of tyrosine 177 of P160 BCR. That Bcr has the potential to activate the Ras pathway is strengthened by the report of Braselmann and McCormick (1995) , demonstrating that Bcr is bound to membrane bound Raf via 14-3-3. Thus, Raf bound to Ras at the inner surface of the plasma membrane could bring Bcr in close association with Ras. Bcr, which is phosphorylated on tyrosine 177, would then bind Grb2 and mSos. The end result would be activating Ras by changing it to the GTP state. However, it remains to be shown whether these observations re¯ect an important physiological role for P160 BCR in normal cellular function. These ®ndings also suggest that the Bcr protein may, in a similar manner, supplement the Bcr-Abl protein's ability to activate the Ras pathway in leukemic cells, as Bcr/Bcr-Abl hetero-tetramers could similarly be delivered to Ras via Raf/14-3-3 complexes.
We and others demonstrated that tyrosine phosphorylation of Bcr sequences within Bcr-Abl by the constitutively active tyrosine kinase of Bcr-Abl represents a pathological phenomenon in pH-positive leukemias (Pendergast et al., 1993 and Puil et al., 1994) . As a result it was assumed that the Bcr protein was tyrosine phosphorylated only in cells expressing Bcr-Abl. However, the studies shown here strongly suggest that the Bcr protein could undergo tyrosine phosphorylation by the c-Abl tyrosine kinase in normal hematopoietic cells. Therefore, it will be of interest to determine whether tyrosine phosphorylation of Bcr occurs at a speci®c stage of cell dierentiation or phase of the cell cycle. Of interest, a report by Maru et al. (1995) demonstrated that tyrosine phosphorylation of Bcr by the Fps/Fes protein tyrosine kinases induces association of Bcr with Grb2/Sos. Thus, it seems likely that Bcr can serve as a substrate and potential eector for several cytoplasmic tyrosine kinases, linking them to the Ras pathway.
